Published in final edited form as:

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 June 01; 991: 118–121. doi:10.1016/j.jchromb.2015.04.011.

Chromatographic separation of PTAD-derivatized 25-hydroxyvitamin D₃ and its C-3 epimer from human serum and murine skin

Matthew D. Teegarden, Kenneth M. Riedl, Steven J. Schwartz*

Department of Food Science and Technology, The Ohio State University, United States

Abstract

The detection of 25-hydroxyvitamin D at low levels in biological samples is facilitated by the use of chemical derivatization with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) in concert with liquid chromatography–tandem mass spectrometry (LC–MS/MS). This mode of analysis is notably hampered by chromatographic co-elution of 25-hydroxyvitamin D₃ (25OHD₃) and its C-3 epimer (C3epi). The objective of this work was to improve upon current LC–MS/MS methods used for the analysis of PTAD-derivatized 25-hydroxyvitamin D₃ by resolving it from C3epi. Additionally, the applicability of this method in human serum and murine skin was investigated. C18 columns of increasing length and varying particle sizes were assessed for performance using a mixed standard of PTAD-derivatized 25OHD₃ and C3epi. Serum samples were processed using solid phase extraction, and skin was powdered and extracted for lipophilic compounds. The samples were derivatized with PTAD and subsequently analyzed using isotope dilution LC–MS/MS with atmospheric pressure chemical ionization operated in positive mode. Near baseline resolution of PTAD-25OHD₃ from PTAD-C3epi was achieved on a 250 mm C18 column with 3 μm sized particles. This separation allowed for detection and quantification of both metabolites in serum and skin samples. PTAD-C3epi represented a significant confounding analyte in all samples, and comprised up to 20% of the status measurement in skin. This method is a significant improvement on the chromatography of PTAD-derivatized vitamin D metabolites that could greatly influence the assessment of vitamin D status and C3epi biology in low abundance samples.

Keywords

25-Hydroxyvitamin D analysis; C3-epi-25-hydroxyvitamin D; HPLC–MS/MS; PTAD; Vitamin D

1. Introduction

Determination of vitamin D status, serum 25-hydroxyvitamin D (25OHD), has been a notable challenge in clinical and research laboratories, as there are inconsistencies between methods used for measurement and between laboratories performing the assays [1]. Among modern methods for 25OHD measurement, high performance liquid chromatography coupled with tandem mass spectrometry (HPLC–MS/MS) is the gold standard, albeit this

*Corresponding author at: 2015 Fyffe Ct., Columbus, OH 43210, United States. Tel.: +1 614 292 2934; fax: +1 614 292 0218. Schwartz.177@osu.edu(S.J. Schwartz).

method is not devoid of challenges [2]. Perhaps the most notable challenge in HPLC–MS/MS analysis of vitamin D status is the presence of 3-epi-25-hydroxyvitamin D (C3epi), which behaves similarly to 25OHD with respect to both MS/MS fragmentation and chromatography. The biological activity of C3epi is known to be less than that of native 25OHD, though the exact bioequivalence is still unknown [3]. Thus, resolution of these two compounds is essential for proper measurement of vitamin D status. Once only of concern as a false positive in infants less than one year of age [4], recent work has shown that C3epi is also present in the serum of adults at significant levels [5,6]. The presence of this metabolite in biological samples aside from serum has also been left largely unexplored.

In order to increase the sensitivity of HPLC–MS/MS methods, several groups have begun employing chemical derivatization with Cookson-type reagents. These compounds are 4-substituted 1,2,4-triazoline-3,5-diones that react with conjugated diene systems in a Diels–Alder fashion [7]. A number of Cookson-type reagents have been suggested for use in vitamin D analysis [8], but the most prevalent is commercially available 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD). The chromatography of these compounds is notably challenging because (*R*) and (*S*) isomers of each metabolite are created as a result of the derivatization process [9]. To our knowledge, no chromatographic method that adequately separates PTAD-derivatized C3epi from 25OHD has been published.

The objective of this work was to develop an HPLC–MS/MS method that allows for sensitive and selective measurement of PTAD-derivatized 25OHD₃ and C3epi in serum as well as murine skin as an example extrahematic matrix. This will allow further study of vitamin D status in biological samples containing low amounts of vitamin D metabolites.

2. Materials and methods

2.1. Biological samples

All mice used in this work were housed in a vivarium at The Ohio State University according to standards established by the American Association for Accreditation of Laboratory Animal Care, and procedures were approved by the appropriate Institutional Animal Care Utilization Committee. These male Skh-1 mice were fed modified AIN-93G diets containing 25, 150, or 1000 IU vitamin D₃ provided with water *ad libitum* for 29 weeks. Human serum and pooled umbilical cord serum were acquired from Innovative Research (Novi, MI).

2.2 Chemicals

Optima grade water, acetonitrile, methanol, hexane, HPLC grade dichloromethane, and 99% formic acid were obtained from Fisher Scientific (Pittsburgh, PA). 25OHD₃ was obtained from Isosciences (King of Prussia, PA) and d3-25OHD₃, C3epi, and PTAD were obtained from Sigma Aldrich (St. Louis, MO).

2.3 Sample preparation

Mixed standards of 25OHD₃ and C3epi ranging in concentration from 7.80 to 250 nM were spiked with 20 µL of a d3-25OHD₃ solution (200 nM in acetonitrile), dried, and set aside.

Skin samples (0.30 g) were frozen with liquid nitrogen, crushed to a fine powder using a Cellcrusher (Cellcrusher Ltd.; Cork, Ireland), and transferred to glass vials. The powdered skin was then suspended in 1 mL of water, spiked with 10 μ L of the d3-25OHD₃ solution, allowed to equilibrate for 15 min, and extracted for lipophilic compounds as previously described [10,11]. Briefly, 1 mL of ethanol containing 0.1% butylated hydroxytoluene and 5 mL of 5:1 hexane/dichloromethane were added to the skin samples, and the mixture was probe sonicated (Branson Ultrasonics; Danbury, CT) for 30 s. The homogenized solutions were centrifuged at $2000 \times g$ for 5 min, and the upper organic layer was decanted into clean glass vials. The extraction was repeated two more times, with the addition of 5 mL 5:1 hexane/dichloromethane, and the pooled organic layers were dried under a stream of nitrogen gas.

Serum samples were extracted using PhreeTM SPE cartridges (1 mL tubes; Phenomenex, Torrance, CA) according to the Phenomenex technical protocol [12] with minor changes. First, 200 μ L of serum was deposited into an SPE cartridge, spiked with 20 μ L of the d3-25OHD₃ solution, and allowed to equilibrate for 15 min. Then, 500 μ L of an 85:15 acetonitrile/methanol solution was added to the cartridge, vortexed for 30 s, allowed to rest for 1 min, and eluted under vacuum (-50 kPa) for 2 min. The extraction was repeated once more and the pooled eluents were dried under a stream of nitrogen gas.

Dried extracts and standards were derivatized with PTAD according to Lipkie et al. [13]. Briefly, 100 μ L of a 2 mg/mL PTAD solution was added to the extracts, which were then vortexed for 10 min. An additional 100 μ L of PTAD was added to the solution and mixing was repeated for another 10 min. The reaction was quenched by adding 20 μ L of water and vortexing for 5 min, and the reaction mixture was dried under nitrogen gas. Skin extracts were reconstituted with 100 μ L of acetonitrile, and centrifuged at $21,130 \times g$ for 2 min prior to analysis. Serum extracts were reconstituted with 200 μ L acetonitrile and passed through 0.22 μ m, 4 mm nylon filters (W.R. Grace; Deerfield, IL) before injection (10 μ L) onto the HPLC–MS/MS system.

2.4. Method development and biological sample analysis

Details of the HPLC columns which were evaluated for the resolution of PTAD-C3epi and PTAD-25OHD₃ are summarized in Table 1. Each column was evaluated using a mixed standard of PTAD-derivatized 25OHD₃ (100 nM) and C3epi (100 nM) with a binary mobile phase consisting of 0.1% (v/v) aqueous formic acid solution (A) and acetonitrile with 0.1% (v/v) formic acid (B) on an Agilent 1200 series HPLC (Santa Clara, CA). Mobile phase composition was adjusted for the varying column geometries. Eluent from the HPLC was directed to a QTRAP 5500 mass spectrometer (AB Sciex; Framingham, MA) equipped with atmospheric pressure chemical ionization (APCI) operated in positive ion mode. MS parameters were as follows: source temperature, 450°C; collision energy, 25 eV; dwell time, 280 ms; curtain gas, 30 psi; ion source gas, 60 psi; declustering potential, 185 V; entrance potential, 10 V; collision cell exit potential, 11 V. PTAD-25OHD₃ and PTAD-C3epi were monitored from $558.3 > 298.3$ m/z , and PTAD-d3-25OHD₃ was monitored from $561.3 > 301.3$ m/z .

Vitamin D metabolites from biological samples were separated using a Luna C18 reversed phase column (4.6 mm × 250 mm, 3 μm; Phenomenex) maintained at 40°C. Optimal separation was achieved using an isocratic flow of 29% A for 3.5 min with an immediate switch to 20% A for 3 min, followed by a column wash with 100% B for 2 min and reconditioning at initial conditions for 3.5 min. The injection needle was rinsed with acetonitrile before each injection to minimize carryover. Eluent from the HPLC was directed to the QTRAP system described above.

Peaks were integrated in Analyst 1.5.1 (AB Sciex, Framingham, MA). Areas of both PTAD-25OHD₃ isomers were summed and used for quantification. Isotope dilution methodology was utilized for quantification, thus analyte concentrations were calculated based on the ratio of analyte peak area to that of the labeled internal standard.

3. Results and discussion

Varying the dimensions of the C18 columns greatly influenced the separation of PTAD-derivatized 25OHD₃ and C3epi. As column length was increased above 50 mm, three peaks were clearly observed (Fig. 1). Peak identities were confirmed using separate solutions of PTAD-derivatized 25OHD₃ and C3epi standards. 6(*R*)-PTAD-25OHD₃ and 6(*S*)-PTAD-25OHD₃ were resolved and present in an approximately 1:4 ratio, as has been described previously [9]. Both 6(*R*)-PTAD-C3epi and 6(*S*)-PTAD-C3epi co-eluted as a single peak between the two PTAD-25OHD₃ diastereomers. The best resolution of PTAD-C3epi from 6(*S*)-PTAD-25OHD₃ was achieved with the 4.6 mm × 250 mm Luna C18 column with a 3 μm particle size.

This methodology was tested using different sample matrices including adult serum, pooled umbilical cord serum, and murine skin (Table 2). Representative serum and skin chromatograms are shown in Fig. 2. These samples were selected not only because of their different physical and chemical matrices but also because they were expected to contain differing proportions of C3epi and 25OHD₃. The ratio of both metabolites were similar in the adult serum and pooled cord serum, with C3epi comprising between 5.7% and 7.4% of the total vitamin D status measurement in the adult sera and 7.8% in the cord serum. These proportions are in close agreement with previously published results for both adults [5,6] and infants [4]. This is the first report of skin levels of 25OHD₃ and C3epi in mice, and the levels of 25OHD₃ are comparable to those in fat, muscle, and liver of rats, as reported by Lipkie and colleagues [13]. If left unresolved, C3epi would have represented a range between 3.7% and 22.1% of the total 25OHD₃ measurement in skin.

Little is known about the biological relevance of C3epi, and it represents a source of false positive bias in HPLC–MS/MS measurement of vitamin D status [1]. Cell studies have revealed that C3epi can be activated by CYP27B1 to C3epi-1,25(OH)₂D₃, which binds weakly to the vitamin D receptor and elicits muted biological responses [3,14]. Interest in further elucidating the role of C3epi is growing, as demonstrated by recent human studies specifically investigating this compound [4-6,15-18] and an increasing number of methods designed to resolve underivatized 25OHD₃ from C3epi [19-25].

Simultaneous to this increased interest in quantification of C3epi, new investigations into the content of vitamin D metabolites in tissues are on the rise. Some of these were limited by sample size or analyte concentration, and thus utilized PTAD derivatization to enhance MS/MS signal [13,26,27]. The present study is the first account of near-complete chromatographic resolution of PTAD-derived C3epi and 25OHD₃, thus allowing separate detection of these compounds in samples with low abundance of analytes. Previous work with these analytes did not show complete separation [28,29]. Higashi and colleagues developed a method to separate PTAD-derivatized C3epi and 25OHD, but separation was only possible after acetylation of the PTAD-metabolites [30]. The method described here is just a single derivatization step and achieves similar chromatographic resolution. Another derivatizing agent, 4-(4'-dimethylaminophenyl)-1,2,4-triazoline-3,5,-dione (DAPTAD), which allows for separation of these two metabolites has been proposed [31], but this compound is not commercially available. The chromatographic method described in this work satisfies the needs of emerging areas of vitamin D research, as it allows for separation of C3epi and 25OHD₃ with increased sensitivity imparted by PTAD derivatization.

4. Conclusions

Presented in this work is an improvement over current chromatographic methods used for PTAD-derivatized 25OH D₃, allowing resolution of PTAD-C3epi and thus a more accurate vitamin D status measurement. Preliminary evidence suggests that C3epi is present in murine skin in higher proportions than those found in human serum. Assessment of other tissues will provide more complete data on the biological distribution of C3epi and allow its production and function *in vivo* to be assessed.

Acknowledgements

We would like to thank Tatiana Oberyszyn and Kathleen Tober (College of Medicine, The Ohio State University) for their generous gift of the murine samples used in this work and Jessica Cooperstone for her editorial assistance. We would also like to thank the Nutrient and Phytochemical Analytic Shared Resource in the Comprehensive Cancer Center at The Ohio State University for their support in developing this method and the Food Innovation Center at The Ohio State University for funding this work.

Abbreviation:

PTAD: 4-phenyl-1,2,4-triazole-3,5-dione.

References

- [1]. Bedner M, Lippa KA, Tai SS-C, Clin. Chim. Acta 426 (2013) 6. [PubMed: 23978484]
- [2]. Zerwekh JE, Am. J. Clin. Nutr 87 (2008) 1087S. [PubMed: 18400739]
- [3]. Bailey D, Veljkovic K, Yazdanpanah M, Adeli K, Clin. Biochem 46 (2013) 190. [PubMed: 23153571]
- [4]. Singh RJ, Taylor RL, Reddy GS, Grebe SKG, J. Clin. Endocrinol. Metab 91 (2006) 3055. [PubMed: 16720650]
- [5]. Lensmeyer G, Poquette M, Wiebe D, Binkley N, J. Clin. Endocrinol. Metab 97 (2012) 163. [PubMed: 22013102]
- [6]. Cashman KD, Kinsella M, Walton J, Flynn A, Hayes A, Lucey AJ, Seamans KM, Kiely M, Nutr J. 144 (2014) 1050.
- [7]. Shimada K, Oe T, Mizuguchi T, Analyst 116 (1991) 1393.

- [8]. El-Khoury JM, Reineks EZ, Wang S, Clin. Biochem 44 (2011) 66. [PubMed: 20493831]
- [9]. Higashi T, Shibayama Y, Fuji M, Shimada K, Anal. Bioanal. Chem 391 (2008) 229. [PubMed: 18087693]
- [10]. Kopec RE, Bioavailability, Metabolism, and Bioefficacy of Tomato Carotenoids, The Ohio State University, 2012.
- [11]. Conlon LE, King RD, Moran NE, Erdman JW, Agric J. Food Chem. 60 (2012) 8386.
- [12]. Huq S, Safan EP, Rapid and Effective Cleanup of Vitamin D2 and D3 from Human Plasma Using Phree Phospholipid Removal Plates and Kinetex Core–Shell HPLC/UPLC Columns, Torrance, CA, n.d.
- [13]. Lipkie TE, Janasch A, Cooper BR, Hohman EE, Weaver CM, Ferruzzi MG, J. Chromatogr. B 932 (2013) 6.
- [14]. Kamao M, Tatematsu S, Hatakeyama S, Sakaki T, Sawada N, Inouye K, Ozono K, Kubodera N, Reddy GS, Okano T, J. Biol. Chem 279 (2004) 15897. [PubMed: 14757768]
- [15]. Shah I, Petroczi A, Naughton DP, J. Clin. Endocrinol. Metab 99 (2014) 808. [PubMed: 24423328]
- [16]. Karras SN, Shah I, Petroczi A, Goulis DG, Bili H, Papadopoulou F, Harizopoulou V, Tarlatzis BC, Naughton DP, Nutr. J 12 (2013) 77. [PubMed: 23911222]
- [17]. Stepman HCM, Vanderroost A, Stöckl D, Thienpont LM, Clin. Chem. Lab. Med 49(2011)253. [PubMed: 21143012]
- [18]. Strathmann FG, Sadilkova K, Laha TJ, LeSourd SE, Bornhorst JA, Hoofnagle AN, Jack R, Clin. Chim. Acta 413 (2012) 203. [PubMed: 21983164]
- [19]. Clarke MW, Tuckey RC, Gorman S, Holt B, Hart PH, Metabolomics 9 (2013) 1031–1040.
- [20]. Schleicher RL, Encisco SE, Chaudhary-Webb M, Paliakov E, McCoy LF, Pfeiffer CM, Clin. Chim. Acta 412 (2011) 1594. [PubMed: 21601563]
- [21]. Phinney KW, Bedner M, Tai SS-C, Vamathevan VV, Sander LC, Sharpless KE, Wise SA, Yen JH, Schleicher RL, Chaudhary-Webb M, Pfeiffer CM, Betz JM, Coates PM, Picciano MF, Anal. Chem 84 (2012) 956. [PubMed: 22141317]
- [22]. Yazdanpanah M, Bailey D, Walsh W, Wan B, Adeli K, Clin. Biochem. 46(2013) 1264. [PubMed: 23269360]
- [23]. vandenOuweland JMW, Beijers AM, vanDaal H, Clin. Chem 57(2011)1618. [PubMed: 21914787]
- [24]. Shah I, James R, Barker J, Petroczi A, Naughton DP, Nutr.J 10 (2011) 46. [PubMed: 21569549]
- [25]. Baecher S, Leinenbach A, Wright JA, Pongratz S, Kobold U, Thiele R, Clin. Biochem 45(2012)1491. [PubMed: 22771503]
- [26]. Burild A, Frandsen HL, Poulsen M, Jakobsen J, Steroids 98 (2015) 72–79. [PubMed: 25725256]
- [27]. Burild A, Frandsen HL, Poulsen M, Jakobsen J, J. Sep. Sci 37 (2014) 2659. [PubMed: 25045048]
- [28]. Laha TJ, Strathmann FG, Wang Z, De Boer IH, Thummel KE, Hoofnagle AN, Clin. Chem 58 (2012) 1711. [PubMed: 22968104]
- [29]. Gallo S, Comeau K, Vanstone C, Agellon S, Sharma A, Jones G, L'Abbe M, Khamessan A, Rodd C, Weiler H, J. Am. Med. Assoc 309 (2013) 1785.
- [30]. Higashi T, Suzuki M, Hanai J, Inagaki S, Min JZ, Shimada K, Toyo'oka T, J. Sep. Sci 34 (2011) 725. [PubMed: 21328697]
- [31]. Ogawa S, Ooki S, Morohashi M, Yamagata K, Higashi T, Rapid Commun. Mass Spectrom 27 (2013) 2453. [PubMed: 24097402]

Fig. 1.

Improvement of chromatographic resolution of a mixed standard containing PTAD-derivatized 25OHD₃ and C3epi with C18 columns of varying length and particle size (a: Zorbax Extend; b: Symmetry; c: Eclipse; d: Luna 5 μm; e: Luna 3 μm). Peak identities in chromatogram e include 6(*R*)-PTAD-25OHD₃ (1), (*R*)- and (*S*)-PTAD-C3epi (2), and 6(*S*)-PTAD-25OHD₃ (3); peaks 1 and 3 were summed for quantitation of 25OHD₃.

Fig. 2. Representative chromatograms of vitamin D metabolites in human adult serum (a) and murine skin (b). Peak identities in chromatogram a include 6(*R*)-PTAD-25OHD₃ (1), (*R*)- and (*S*)-PTAD-C3epi (2), and 6(*S*)-PTAD-25OHD₃ (3).

Table 1

Details of evaluated HPLC columns.

Column name	Particle size (μm)	Dimensions (mm × mm)	Manufacturer
Zorbax extend UHPLCC18 HT	1.8	2.1 × 50	Agilent ^a
Symmetry C18	3.5	4.6 × 75	Waters ^b
Eclipse XDB-C18	5.0	4.6 × 150	Agilent
Luna C18(2)	5.0	4.6 × 250	Phenomenex ^c
Luna C18(2)	3.0	4.6 × 250	Phenomenex

^aSanta Clara, CA.^bMilford, MA.^cTorrance, CA.

Table 2Levels of 25OHD₃ and C3epi from a variety of sample matrices.

Sample	25OHD ₃ (nmol/L)	C3epi (nmol/L)
Cord serum	42.4	3.6
Adult serum 1	90.2	5.5
Adult serum 2	47.4	3.4
Adult serum 3	57.2	4.6
	(pmol/g)	(pmol/g)
Skin 1	2.4	0.18
Skin 2	3.4	0.13
Skin 3	7.4	2.1